Analysis highlights access-related challenges involving bevacizumab reimbursement in metastatic cervical cancer care in Asia-Pacific.
Table S6 shows access-related challenges reported by respondents in locations where bevacizumab is publicly reimbursed
No takes yet. Share an insight, caveat, or question.
Goh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: